<i>Cin85</i>-Deficiency results in defective clearance of LCMV-c13 and is correlated with decreased neutralizing antibody titer. by Saravanan Raju (5181014)

Decreased Autophagy in Rat Heart Induced by Anti-β1-Adrenergic Receptor Autoantibodies Contributes to the Decline in Mitochondrial Membrane Potential by Li Wang (15202)

“…Male adult rats were randomized to receive a vehicle or peptide corresponding to the second extracellular loop of the β₁ adrenergic receptor (β₁-AAB group, 0.4 μg/g every two weeks for 12 weeks) and treated with rapamycin (RAPA, an autophagy agonist) at 5 mg/kg/day for two days before detection. …”

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and log-rank test. A Cox regression model was performed to identify independent prognostic factors.…”

Lack of Brain Insulin Receptor Substrate-1 Causes Growth Retardation, with Decreased Expression of Growth Hormone-Releasing Hormone in the Hypothalamus by Takanori Hayashi (5185250)

Substitutions of amino acids 605 and 606 in PB2 affect RNP activity in an NP-dependent manner. by Ho-Pan Hsia (4768638)

Reducing AHP duration in mice with upregulated astroglial Cx30 restores pyramidal cell excitability and excitatory synaptic transmission. by Eléonore Hardy (15208385)

The Response of <em>Thalassiosira pseudonana</em> to Long-Term Exposure to Increased CO₂ and Decreased pH by Katharine J. Crawfurd (198710)

The 11R-VIVIT peptide inhibitor of NFATs decreases bacterial phagocytic killing capacity by neutrophils and increases renal susceptibility to UPEC. by Emilie Tourneur (278826)

WNT3 decreases the GCP proliferation marker <i>Atoh1</i> and increases the GCP differentiation marker PAX6. by Sandrine L. Anne (489755)

“…<p>(<i>A</i>) WNT3 decreased <i>Atoh1</i> mRNA levels after 6 h of treatment (Con=1; WNT3: <i>Atoh1</i>=0.52±0.06). …”

Number and percentage of adverse drug reaction reports associated with PREPARE drugs that have a pharmacogneomic indication for the gene SLCO1B1 stratified by decade. by Emma F. Magavern (20947928)

Number and percentage of adverse drug reaction reports associated with PREPARE drugs that have a pharmacogneomic indication for the gene CYP2C19 stratified by decade. by Emma F. Magavern (20947928)

Number and percentage of adverse drug reaction reports associated with PREPARE drugs that have a pharmacogneomic indication for the gene CYP2D6 stratified by decade. by Emma F. Magavern (20947928)

Image_2_Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease.JPEG by Meijuan Liu (4924417)

“…At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05).…”

Image_1_Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease.JPEG by Meijuan Liu (4924417)

“…At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05).…”

Table_1_Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease.DOCX by Meijuan Liu (4924417)

“…At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05).…”

Image 2_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Methods<p>Mice were inoculated with 10⁷ CFU of the eubiotic bacteria Lactobacillus crispatus, the dysbiotic bacteria G. vaginalis, or PBS as a negative control every 48 h for ten days. On day ten, mice were inoculated with 10⁵ PFU WT HSV-2 333 and survival, pathology, and viral titers were assessed. …”

Image 3_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Methods<p>Mice were inoculated with 10⁷ CFU of the eubiotic bacteria Lactobacillus crispatus, the dysbiotic bacteria G. vaginalis, or PBS as a negative control every 48 h for ten days. On day ten, mice were inoculated with 10⁵ PFU WT HSV-2 333 and survival, pathology, and viral titers were assessed. …”

Image 1_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Methods<p>Mice were inoculated with 10⁷ CFU of the eubiotic bacteria Lactobacillus crispatus, the dysbiotic bacteria G. vaginalis, or PBS as a negative control every 48 h for ten days. On day ten, mice were inoculated with 10⁵ PFU WT HSV-2 333 and survival, pathology, and viral titers were assessed. …”

Image 4_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Methods<p>Mice were inoculated with 10⁷ CFU of the eubiotic bacteria Lactobacillus crispatus, the dysbiotic bacteria G. vaginalis, or PBS as a negative control every 48 h for ten days. On day ten, mice were inoculated with 10⁵ PFU WT HSV-2 333 and survival, pathology, and viral titers were assessed. …”

Substitutions of amino acids 601 to 607 of the PB2 ‘627’ domain disrupt RNP activity. by Ho-Pan Hsia (4768638)